
Investigators have discovered active substances that can block the replication of coronavirus and may create a pathway for new therapies.
Investigators have discovered active substances that can block the replication of coronavirus and may create a pathway for new therapies.
A review of emergency room records showed a very small percentage of patients had acute ischemic strokes, but for those who did, there was an increased risk of requiring long-term care after hospital discharge.
Cells reactive to SARS-CoV-2 peptide pools were found in all anti-NP IgG–positive individuals.
Novel positive controls offer several advantages over the ones currently used in COVID-19 testing.
SARS-CoV-2 infects cardiomyocytes through an ACE2 and endosomal inflammatory infiltrate.
NeuroRx announced results from its phase 2b/3 trial for its investigational therapy, aviptadil, in patients with severe COVID-19.
The committee encourages those eligible to receive the vaccine when available to them.
SARS-CoV-2 infection is known to result in a number of extrapulmonary manifestations.
The Biden Administration is set to announce the deal officially about a partnership for the biopharmaceutical companies today.
A research team recently sought to address this by assessing SARS-CoV-2 positivity in students on or after 9 days after an exposure.
A review of approximately 1000 children with multisystem inflammatory syndrome (MIS-C) from SARS-Cov-2 finds low fatality with aggressive treatment.
Prime Minister Narendra Modi of India receives vaccine as country begins next phase of program.
Courtesy of HCPLive, here's a look at 3 new pandemic talking points covered at the annual allergy and asthma meeting.
How observed changes in SARS-CoV-2 lineage have warranted heightened priority, and why sequencing deserves better resourcing beyond the pandemic.
The variant, B.1.526, was first found in samples dating back to November.
Symptoms of COVID-19 can persist for months in about a third of cases, including among those with mild illness, a new study confirms.
The VRBPAC voted 22-0 with no abstentions to support the benefit-risk profile associated with Ad26.COV2.S on Friday night.
Vitamin B6 is a water-soluble vitamin found in various foods such as fish, whole grains, and bananas.
The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation paves the way for the authorization.
Patients with cardiometabolic conditions have a high risk of poor outcomes.
The country has no domestic production, and the government has been accused of not acquiring doses quickly enough.
A team of cross-country investigators discuss their coordinated tracking of a new variant in the US earlier this year.
Multiple observational and ex-vivo laboratory studies have demonstrated that IL-6 is an important cytokine associated with disease severity and mortality.
If approved, the decision could have a significant impact on the mass vaccination programs.
In a phase 3 study, rheumatoid arthritis (RA) therapy, tocilizumab, did not improve clinical status or lower mortality in these patients.